Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish MarketGlobeNewsWire • 09/11/24
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic DeviceZacks Investment Research • 09/10/24
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube CheckGlobeNewsWire • 09/09/24
Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual MeetingGlobeNewsWire • 09/05/24
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment SolutionGlobeNewsWire • 08/29/24
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate UpdateGlobeNewsWire • 08/08/24
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in AmsterdamGlobeNewsWire • 06/27/24
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate UpdateGlobeNewsWire • 05/09/24
Femasys Expands Commercial Management Team with Addition of Experienced New HiresGlobeNewsWire • 05/07/24
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/02/24
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare InitiativesGlobeNewsWire • 04/18/24
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate UpdateGlobeNewsWire • 03/28/24
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment LandscapeGlobeNewsWire • 03/21/24
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of InfertilityGlobeNewsWire • 03/20/24
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionGlobeNewsWire • 03/06/24
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFGlobeNewsWire • 02/28/24
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial OfficerGlobeNewsWire • 02/06/24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for WomenGlobeNewsWire • 01/26/24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and GynecologyGlobeNewsWire • 01/23/24